anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: stomatology. SUBSTANCE: adhesive composition contains mixed salts of alkyl vinyl ether/maleic acid copolymer or alkyl vinyl ether/maleic anhydride copolymer, and/or alkyl vinyl ether/maleic anhydride/isobutylene terpolymer wherein cation constituent can be strontium and zinc cations; cation selected from group containing: iron, boron, aluminum, vanadium, chromium, manganese, nickel, copper, yttrium, titanium, and their mixtures; free acid component; and cation selected from magnesium, calcium, and their mixtures. Invention also relates to adhesive composition for dental prosthetics containing above-indicated composition and at least one inadhesive selfcarrying layer. All components are used un specified quantitative proportions. Invention also provides method of increasing adhesion of dental prostheses to oral cavity, for which composition of invention is applied on dental prostheses, directly on oral cavity, palate, or alveolar process in oral cavity, after which dental prosthesis is fixed. EFFECT: increased fixation reliability. 10 cl, 4 tbl, 4 ex
The invention relates to the field of therapeutic chemistry and concerns novel antiviral pharmaceutical compositions for the local prevention of diseases of the genital and rectal mucus membranes. The compositions are characterized in that that the active ingredient used is riboflavin or one of the mineral or organic acid or FAD addition salts thereof. The active ingredient further comprises niacin or NAD or NADP. Vitamin factors can also be added such as carotene, flavonoids, acetyloenzyme A and vitamins A, E, C, B6, B8 or F. Fillers such as insoluble barium salts, titanium derivatives, alkaline-earth silicates, aluminium silicates, mineral or organic bismuth salts, insoluble zinc salts, rare earth derivatives, zirconium derivatives, can be added to said compositions to reinforce the mucus adhesiveness of said preparations. Vegetable extracts containing flavonoids or anthocyanosides can be further incorporated into the pharmaceutical compositions of the invention. The preferred pharmaceutical preparations take the form of creams, gels, lotions, viscous emulsions, suppositories, ovules, capsules, vaginal tablets and the like. The initial claimed effect is primarily the prevention of sexually transmissable viral diseases, namely AIDS, genital herpes and the papillomavirus.
Agent that selectively inhibit CD25 on dendritic cells on T cells are disclosed herein. Methods are provided for treating a subject with an immune mediated disease. These methods include administering to the subject a therapeutically effective amount of an agent that selectively inhibits CD25 on dendritic cells, thereby treating the immune mediated disorder in the subject. In other embodiments, methods are provided for treating a subject with a tumor. The methods include administering to the subject a therapeutically effective amount of an agent that selectively inhibits CD25 on T cells, thereby treating the tumor in the subject. Compositions are disclosed that include a composite molecule and a carrier, wherein the composite molecule comprises an agent that selectively binds dendritic cells or an agent that selectively binds T cells, wherein the agent is covalently bound to a CD25 antagonist. Methods for selecting an agent of use in treating an immune mediated disorder are also disclosed.
FIELD: medicine, phthisiology, pharmacology. SUBSTANCE: invention relates to the combined antituberculosis preparation. The combined antituberculosis preparation comprises rifampicin, ethambutol, isoniazide, pyrazinamide and pyridoxine taken in the definite ratio of components. Invention provides the enhancement of effectiveness of therapy due to simplification of curative process, resistance overcoming in many patients and improvement of the preparation properties. EFFECT: enhanced effectiveness of preparation and treatment. 6 tbl
A class of anionic oligomers and polymers that function for inhibition of nucleases, particularly RNase. Specific inhibitors include mixtures of oligomers of vinyl sulfate. Methods for inhibition or inactivation of one or more nucleases in vitro which comprises the step of contacting the one or more nucleases in a biological medium with one or more of the anionic oligomeric or polymeric inhibitors of this invention. Kits for carrying out a biological procedure, biological reaction and/or a biological assay containing one or more inhibitors of this invention. The use of oligomers and/or polymers of this invention as additives in buffers or reagents. The inhibitors of the invention can also be attached to surfaces to provide for removal of nucleases from media, solutions or other liquids in contact with the solid.
Procedure/Surgery: vagus nerve-guided group The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
NEW MATERIAL:Compounds of formula I (R1 to R4 are H or methyl; m and n are 2 and 3; k and l are 0-4). USE:Useful as a raw material of inks, coating materials, adhesives, various covering materials, molding resins, etc., and especially useful as a crosslinking agent. Having resistance to polymerization inhibition due to oxygen and capable of improving crosslink density and hardness without embrittlement when used as a crosslinking agent. PREPARATION:With 2,2-bis(4'-hydroxyphenyl)hexafluoropropane or an alkylene glycol ether thereof of formula II an isocyanatealkyl (meth)acrylate of formula III and/or formula IV is reacted in a solvent such as dichloromethane using a catalyst (e.g. dibutyltin dilaurate) and a polymerization inhibitor (e.g. phenothiazine) to obtain the objective compound of formula I.
BACKGROUND: Most previous studies investigating the associations between prenatal exposure to phthalates and fetal growth relied on measurements of phthalate metabolites at a single time point. They also focused on weight at birth without assessing growth over pregnancy, preventing the identification of potential periods of fetal vulnerability. We examined the associations between pregnancy urinary phthalate metabolites and fetal growth outcomes measured twice during pregnancy and at birth.
METHODS: For 484 pregnant women, we assessed 13 phthalate and two 1,2-cyclohexane dicarboxylic acid, diisononyl ester (DINCH) metabolite concentrations from two within-subject weekly pools of up to 21 urine samples (median of 18 and 34 gestational weeks, respectively). Fetal biparietal diameter, femur length, head and abdominal circumferences were measured during two routine pregnancy follow-up ultrasonographies (median 22 and 32 gestational weeks, respectively) and estimated fetal weight (EFW) was calculated. Newborn weight, length, and head circumference were measured at birth. Associations between phthalate/DINCH metabolite and growth parameters were investigated using adjusted linear regression and Bayesian kernel machine regression models.
RESULTS: Detection rates were above 99 % for all phthalate/DINCH metabolites. While no association was observed with birth measurements, mono-iso-butyl phthalate (MiBP) and mono-n-butyl phthalate (MnBP) were positively associated with most fetal growth parameters measured at the second trimester. Specifically, MiBP was positively associated with biparietal diameter, head and abdominal circumferences, while MnBP was positively associated with EFW, head and abdominal circumferences, with stronger associations among males. Pregnancy MnBP was positively associated with biparietal diameter and femur length at third trimester. Mixture of phthalate/DINCH metabolites was positively associated with EFW at second trimester.
CONCLUSIONS: In this pregnancy cohort using repeated urine samples to assess exposure, MiBP and MnBP were associated with increased fetal growth parameters. Further investigation on the effects of phthalates on child health would be relevant for expanding current knowledge on their long-term effects.
The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) to receive pemetrexed 500 mg/m2 intravenously over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 intravenously over two hours on Day 1 of each 21-day cycle or to receive cisplatin 75 mg/m2 intravenously over 2 hours on Day 1 of each 21-day cycle; treatment continued until disease progression or intolerable toxicity. The study was modified after randomization and treatment of 117 patients to require that all patients receive folic acid 350 mcg to 1000 mcg daily beginning 1 to 3 weeks prior to the first dose of pemetrexed and continuing until 1 to 3 weeks after the last dose, vitamin B12 1000 mcg intramuscularly 1 to 3 weeks prior to first dose of pemetrexed and every 9 weeks thereafter, and dexamethasone 4 mg orally, twice daily, for 3 days starting the day prior to each pemetrexed dose. Randomization was stratified by multiple baseline variables including KPS, histologic subtype (epithelial, mixed, sarcomatoid, other), and gender. The major efficacy outcome measure was overall survival and additional efficacy outcome measures were time to disease progression, overall response rate, and response duration. 

A total of 448 patients received at least one dose of protocol-specified therapy; 226 patients were randomized to and received at least one dose of pemetrexed plus cisplatin, and 222 patients were randomized to and received cisplatin. Among the 226 patients who received cisplatin with pemetrexed, 74% received full supplementation with folic acid and vitamin B12 during study therapy, 14% were never supplemented, and 12% were partially supplemented. Across the study population, the median age was 61 years (range: 20 to 86 years); 81% were male; 92% were White, 5% were Hispanic or Latino, 3.1% were Asian, and <1% were other ethnicities; and 54% had a baseline KPS score of 90-100% and 46% had a KPS score of 70-80%. With regard to tumor characteristics, 46% had Stage IV disease, 31% Stage III, 15% Stage II, and 7% Stage I disease at baseline; the histologic subtype of mesothelioma was epithelial in 68% of patients, mixed in 16%, sarcomatoid in 10% and other histologic subtypes in 6%. The baseline demographics and tumor characteristics of the subgroup of fully supplemented patients was similar to the overall study population. 

The efficacy results from Study JMCH are summarized in Table 18 and Figure 9.

Figure 9: Kaplan-Meier Curves for Overall Survival in Study JMCH

Based upon prospectively defined criteria (modified Southwest Oncology Group methodology) the objective tumor response rate for pemetrexed plus cisplatin was greater than the objective tumor response rate for cisplatin alone. There was also improvement in lung function (forced vital capacity) in the pemetrexed plus cisplatin arm compared to the control arm.
A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP and plans for 5 cycles. CR patients in group B are followed up for observation.
Social isolation and feelings of loneliness are risk factors for older caregivers for family members with Alzheimer's Disease and Related Dementias (ADRD). Further, social isolation and loneliness place older caregivers at risk of poor health, including increased inflammation, cardiovascular disease, depression, and premature mortality. Interventions to promote social connectedness in older caregivers have the potential to reduce elevated morbidity and premature mortality and buffer the high caregiving burden in this growing but understudied population. Thus, developing effective treatments to reduce social disconnectedness in older adults is essential, but previous behavioral treatment efforts have had limited success. Mindfulness-based interventions may reduce loneliness in older adults, as demonstrated in a randomized controlled trial of an 8-week mindfulness-based stress reduction program. Another recent study demonstrated the efficacy of a smartphone-based mindfulness training for reducing loneliness and increasing social contact in daily life among adults reporting above average stress; however, smartphone-based mindfulness training interventions have not been tested with older adults, nor have they been tested with caregivers of family members with ADRD. Specifically, prior studies were conducted with healthy adults not necessarily burdened by caregiving; it remains unknown how caregiver stress --related to competing demands on time and significant loneliness --may impact the ability to comply with the intervention as well as indicate barriers to efficacy. The current study will follow a similar protocol as the aforementioned randomized controlled trial that used a smartphone-based mindfulness training to address loneliness and social contact.
PROBLEM TO BE SOLVED: To provide calcium phosphate cement and calcium phosphate powder with good operability and shaping properties. SOLUTION: Calcium phosphate of the present invention is prepd. by kneading calcium phosphate powder with a solution for curing. As the calcium phosphate, at least one of tricalcium phosphate or tetracalcium phosphate and calcium hydrogenphosphate are preferably incorporated. In addition, as the solution, a reaction accelerator such as an acid is preferable. In the calcium phosphate cement like this, when powder-solution ratio between the calcium phosphate powder and the solution is changed in a range of 1.5-3, the consistency defined by JIS T 6602 is 2-100 mm.
During the controlled epilepsy trials in patients older than 12 years of age receiving doses of NEURONTIN up to 1800 mg daily, somnolence, dizziness, and ataxia were reported at a greater rate in patients receiving NEURONTIN compared to placebo: i.e., 19% in drug versus 9% in placebo for somnolence, 17% in drug versus 7% in placebo for dizziness, and 13% in drug versus 6% in placebo for ataxia. In these trials somnolence, ataxia and fatigue were common adverse reactions leading to discontinuation of NEURONTIN in patients older than 12 years of age, with 1.2%, 0.8% and 0.6% discontinuing for these events, respectively.

During the controlled trials in patients with post-herpetic neuralgia, somnolence, and dizziness were reported at a greater rate compared to placebo in patients receiving NEURONTIN, in dosages up to 3600 mg per day: i.e., 21% in NEURONTIN-treated patients versus 5% in placebo-treated patients for somnolence and 28% in NEURONTIN-treated patients versus 8% in placebo-treated patients for dizziness. Dizziness and somnolence were among the most common adverse reactions leading to discontinuation of NEURONTIN.

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when NEURONTIN is used with other drugs with sedative properties because of potential synergy. In addition, patients who require concomitant treatment with morphine may experience increases in gabapentin concentrations and may require dose adjustment [see Drug Interactions (7.1)].
BACKGROUND: Chronic atrophic gastritis (CAG) is a global digestive system disease and one of the important causes of gastric cancer. The incidence of CAG has been increasing yearly worldwide.
PURPOSE: This article reviews the latest research on the common causes and future therapeutic targets of CAG as well as the pharmacological effects of corresponding clinical drugs. We provide a detailed theoretical basis for further research on possible methods for the treatment of CAG and reversal of the CAG process.
RESULTS: CAG often develops from chronic gastritis, and its main pathological manifestation is atrophy of the gastric mucosa, which can develop into gastric cancer. The drug treatment of CAG can be divided into agents that regulate gastric acid secretion, eradicate Helicobacter. pylori (H. pylori), protect gastric mucous membrane, or inhibit inflammatory factors according to their mechanism of action. Although there are limited specific drugs for the treatment of CAG, progress is being made in defining the pathogenesis and therapeutic targets of the disease. Growing evidence shows that NF-κB, PI3K/AKT, Wnt/ β-catenin, MAPK, Toll-like receptors (TLRs), Hedgehog, and VEGF signaling pathways play an important role in the development of CAG.
<P>PROBLEM TO BE SOLVED: To provide a rapid method for preparing stem cells and physiologically acceptable matrix compositions for use in repair of tissue and organ.  <P>SOLUTION: The stem cell matrix compositions require no long-term incubation or cultivation in vitro prior to use by in vivo applications. The stem cells can stem from numerous sources and may be homogeneous, heterogeneous, autologous and/or allogeneic in the matrix material, and provide practicality at a medical service utility. At this time, the stem cells and matrix can be combined in a short time before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural characteristic to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle, for example, affords contractibility to the matrix composition.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Many drug labels contain precautions of use in G6PD-deficient patients due to hemolytic concerns, but much of this is based on scarce clinical, epidemiological, or structural data. In this real-world study, we aimed to examine if the administration of presumably risky medications for G6PD-deficient patients was followed by hemolysis. The study is based on data from Clalit Health Services database that provides inclusive health care for more than half of the Israeli population (~ 4.7 million). Within the database, we identified all G6PD-deficient patients by G6PD <6 U/g Hb. Within the G6PD-deficient cohort, we identified all hospitalizations with a discharge diagnosis of hemolysis (January 1, 2010 to December 31, 2022), validated the cases, and identified the culprit event. For the rest of the G6PD-deficient patients with no-hemolysis, we recorded filled prescriptions of medications listed as presumably risky. We identified 31,962 G6PD-deficient patients. Within the cohort, there were 71 cases of major hemolysis requiring hospitalization (0.2% of the cohort), of whom 51 (71.8%) had been caused by ingestion of fava beans, six (8.5%) were associated with an infection, and three (4.2%) suggested to be associated with medications (nitrofurantoin, phenazopyridine, and a "pain killer"). Within the 31,875 patients with no major hemolysis, nitrofurantoin has been prescribed safely to 1,366 G6PD-deficient males and females; hundreds/thousands of G6PD-deficient patients had been prescribed safely ciprofloxacin, glibenclamide, ofloxacin, phenazopyridine, sulfamethoxazole/cotrimoxazole, sulfasalazine, hydroxychloroquine, glimepiride, mesalazine, and sulfacetamide. In this real-world study, we are showing that a list of medications, suspected previously as carrying risks for hemolysis in G6PD-deficient patients, have been prescribed safely to G6PD-deficient patients, providing reassurance to patients, prescribers, and regulators.
The invention discloses a recombinant bacillus calmette-guerin vaccine secreting bacteria resuscitation somatomedin and application thereof. The recombinant bacillus calmette-guerin vaccine uses the bacillus calmette-guerin vaccine as host cell. An exogenous expression vector carrying out transfection on the host cell is an expression vector comprising a bacteria resuscitation somatomedin genetic fragment. The recombinant bacillus calmette-guerin vaccine can continuously secrete Rpf factors with bioactivity and can induce a humoral immunity response level and a cellular immune response level. An antibody which is generated by aiming at the exogenous Rpf can interdict the stimulating effect of the Rpf to MTB. The level of inducing IFN-gamma of the recombinant bacillus calmette-guerin vaccine is superior to that of BCG. The recombinant bacillus calmette-guerin vaccine is applied to preparation of a preventive immunity vaccine for MTB infection and/or MTB inapparent infection.
The invention relates to a Reg3 alpha polypeptide (also called liver cancer-intestine-pancreas/pancreatitis related protein (HIP/PAP)) for protecting oxygen sensitive gram positive bacteria, a composition containing the polypeptide and application thereof. The inventors have demonstrated that an increase in the concentration of hReg3a lectin in the gastrointestinal tract (GIT) lumen of hReg3a transgenic mice induces a significant change in the gut microbiota composition and significantly increases host resistance to gut inflammation. hReg3 α has potent antioxidant activity on intestinal epithelial cells during colitis, and in particular ROS scavenging activity, particularly by promoting the survival of hyperoxia-sensitive bacteria. The inventors also demonstrated that hReg3 α transgenic mice are better resistant to DSS-induced colitis after antibiotic treatment. Accordingly, the present invention relates to a Reg3a polypeptide for use in the protection of oxygen sensitive gram positive bacteria, in particular of the family ruminobacteriaceae, such as clostridium prasukii and/or of the family lachnospiraceae, such as ralstonia enterica; pharmaceutical compositions comprising said polypeptides and uses thereof; and the application of the polypeptide in promoting the in vitro growth of oxygen sensitive gram positive bacteria. The Reg3a polypeptide may be used for the prevention or treatment of a microbiota-related disease and/or disorder, in particular selected from Inflammatory Bowel Disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal cancer, metabolic syndrome and obesity, diabetes, liver disease, allergic disease, neurodegenerative disease and psychological disorders.
Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.